In many centres, brachytherapy is the first choice of treatment for uveal melanomas. This modality is also useful for some retinoblastomas and conjunctival tumors. With this form of radiotherapy, a radioactive plaque containing ruthenium-106 or iodine-125 is sutured to the wall of the eye, adjacent to the tumor, and left in place for several days until the required dose of radiation has been delivered.
Eckert & Ziegler BEBIG offers a series of reliable products for temporary brachytherapy of eye cancers. The company is the manufacturer of Ru-106 (Ruthenium-106) Eye Applicators used to treat uveal melanoma and retinoblastoma.
The product portfolio also includes the COMS Eye Applicators used together with IsoSeed® I-125.
For more information, please see www.bebig.com.